Exploring Gallium(III) Complexes as Emerging Therapeutic Candidates for Breast Cancer

Area of Science:

• Medicinal Chemistry
• Inorganic Chemistry
• Cancer Biology

Background:

• Platinum-based chemotherapeutics face limitations due to severe side effects and acquired resistance.
• Gallium compounds offer potential as metallodrugs by mimicking iron(III) and interfering with cellular processes.
• Previous gallium compounds suffered from poor stability and moderate efficacy, hindering their clinical translation.

Purpose of the Study:

• To develop novel gallium(III) complexes with improved stability and enhanced anticancer cytotoxicity.
• To investigate the structure-activity relationship of heteroscorpionate ligands in gallium(III) complexes.
• To evaluate the in vitro and in vivo efficacy and toxicity of promising gallium(III) candidates.

Main Methods:

• Synthesis and characterization of a new family of heteroscorpionate gallium(III) salts ([Ga(κ3-NNO)2][GaCl4], Ga1-Ga6).
• Structural elucidation using NMR spectroscopy and single-crystal X-ray diffraction.
• In vitro cytotoxicity assays against breast cancer cell lines and in vivo studies in zebrafish xenografts and mice.

Main Results:

• The synthesized gallium(III) complexes exhibited excellent air and moisture stability.
• Lipophilicity and solubility were tunable via ligand electronics, with dimethylamino-substituted complexes (Ga3, Ga6) showing nanomolar cytotoxicity.
• The lead compound, Ga6, demonstrated high hydrolytic stability, selective tumor uptake, and significant tumor growth inhibition in zebrafish xenografts with no observable systemic toxicity in mice.

Conclusions:

• Heteroscorpionate gallium(III) complexes represent a promising new class of metallodrugs with potent anticancer activity.
• The developed compounds overcome the limitations of previous gallium agents, offering improved stability and efficacy.
• The lead compound Ga6 warrants further investigation as a potential therapeutic agent for breast cancer treatment.